1. Background
2. Objectives
3. Methods
3.1. Ethics Statement
3.2. Bacterial Isolates
3.3. Molecular Method
3.3.1. Virulence Genotyping
| Genes and Primers | Nucleotide Sequence (5’ - 3’) | Amplicon Size, bp | Annealing Temp., °C | Reference | |
|---|---|---|---|---|---|
| Virulence Genes | |||||
| Adhesion | |||||
| fimH | 640 | 60 | (13) | ||
| F | TACTGCTGATGGGCTGGTC | ||||
| R | GCCGGAGAGGTAATACCCC | ||||
| afa/drABC | 380 | 68 | (14) | ||
| F | ACCCGACGCCGTTTTACATCAACCTG | ||||
| R | CCCTTCCCGCCACCTTTCAGCA | ||||
| papC | 319 | 52 | (14) | ||
| F | TGGATTGTCAGCCTCAAGGTCTA | ||||
| R | CACTGACGCCGAAAGACGTA | ||||
| papG | 1070 | 55 | (15) | ||
| F | CTGTAATTACGGAAGTATTTCTG | ||||
| R | ACTATCCGGCTCCGGATAAACCAT | ||||
| sfaS | 240 | 55 | (15) | ||
| F | GTGGATACGACGATTACTGTG | ||||
| R | CCGCCAGCATTCCCTGTATTC | ||||
| Toxin | |||||
| astA | 390 | 50 | (16) | ||
| F | GCCATCAACACAGTATATCC | ||||
| R | GAGTGACGGCTTTGTAGTCC | ||||
| estA2 | 300 | 53 | (17) | ||
| F | CGCTCAGGATGCTAAACCA | ||||
| R | AATTCACAGCAGTAATTGCT | ||||
| stp | 300 | 53 | (18) | ||
| F | TCTTTCCCCTCTTTTAGTCAG | ||||
| R | ACAGGCAGGATTACAACAAG | ||||
| eltB | 400 | 47 | (19) | ||
| F | ACGGCGTTACTATCCTCTC | ||||
| R | TGGTCTCGGTCAGATATGTG | ||||
| ltA | 200 | 49 | (20) | ||
| F | GGCGACAGATTATACCGTGC | ||||
| R | CGGTCTCTATATTCCCTGTT | ||||
| stx1 | 500 | 55.5 | (16) | ||
| F | ATAAATCGCCATTCGTTGACTAC | ||||
| R | AGAACGCCCACTGAGATCATC | ||||
| stx2 | 213 | 55.5 | (16) | ||
| F | GGCACTGTCTGAAACTGCTCC | ||||
| R | TCGCCAGTTATCTGACATTCTG | ||||
| eaeA | 550 | 55.5 | (16) | ||
| F | GACCCGGCACAAGCATAAGC | ||||
| R | CCACCTGCAGCAACAAGAGG | ||||
| cnf1 | 498 | 55 | (15) | ||
| F | AGGATGGAGTTTCCTATGCAGGAG | ||||
| R | CATTCAGAGTCCTGCCCTCATTATT | ||||
| cnf2 | 543 | 55 | (21) | ||
| F | AATCTAATTAAAGAGAAC | ||||
| R | CATGCTTTGTATATCTA | ||||
| hlyA | 1177 | 55 | (15) | ||
| F | AACAAGGATAAGCACTGTTCTGGC | ||||
| R | ACCATATAAGCGGTCATTCCCGTC | ||||
| Serum resistance | |||||
| traT | 290 | 55 | (15) | ||
| F | GGTGTGGTGCGATGAGCACAG | ||||
| R | CACGGTTCAGCCATCCCTGAG | ||||
| iss | 260 | 50 | (13) | ||
| F | GGCAATGCTTATTACAGGATGTGC | ||||
| R | GAGCAATATACCCGGGCTTCC | ||||
| kapsMTII | 269 | 60 | (14) | ||
| F | GCGCATTTGCTGATACTGTTG | ||||
| R | CATCCAGACGATAAGCATGAGC | ||||
| Iron chelation system | |||||
| iutA | |||||
| F | ATCAGAGGGACCAGCACGC | 253 | 60 | (14) | |
| R | TTCAGAGTCAGTTTCATGCCGT | ||||
| fyuA | |||||
| F | ATACCACCGCTGAAACGCTG | 277 | 60 | (14) | |
| R | CGCAGTAGGCACGATGTTGTA | ||||
| Biofilm encoding gene | |||||
| bssS | |||||
| F | GATTCAATTTTGGCGATTCCTGC | 225 | 60 | (13) | |
| R | TAATGAAGTCATTCAGACTCATCC | ||||
| Pathogenicity Islands (ExPEC PAIs) | |||||
| PAI I536 | 1800 | 55 | (22) | ||
| F | TAATGCCGGAGATTCATTGTC | ||||
| R | AGGATTTGTCTCAGGGCTTT | ||||
| PAI II536 | 1000 | 55 | (22) | ||
| F | CATGTCCAAAGCTCGAGCC | ||||
| R | CTACGTCAGGCTGGCTTTG | ||||
| PAI III536 | 200 | 55 | (22) | ||
| F | CGGGCATGCATCAATTATCTTTG | ||||
| R | TGTGTAGATGCAGTCACTCCG | ||||
| PAI IV536 | 300 | 55 | (22) | ||
| F | AAGGATTCGCTGTTACCGGAC | ||||
| R | TCGTCGGGCAGCGTTTCTTCT | ||||
| PAI ICFT073 | 930 | 56 | (22) | ||
| F | GGACATCCTGTTACAGCGCGCA | ||||
| R | TCGCCACCAATCACAGCGAAC | ||||
| PAI IICFT073 | 400 | 56 | (22) | ||
| F | ATGGATGTTGTATCGCGC | ||||
| R | ACGAGCATGTGGATCTGC | ||||
| PAI IJ96 | 400 | 53 | (22) | ||
| F | TCGTGCTCAGGTCCGGAATTT | ||||
| R | TGGCATCCCACATTATCG | ||||
| PAI IIJ96 | 2300 | 53 | (22) | ||
| F | GGATCCATGAAAACATGGTTAATGGG | ||||
| R | GATATTTTTGTTGCCATTGGTTACC | ||||
| Pathogenicity Islands (DEC PAIs) | |||||
| HPI (irp2) | 287 | 61 | (23) | ||
| F | AAGGATTCGCTGTTACCGGAC | ||||
| R | TCGTCGGGCAGCGTTTCTTCT | ||||
| Tia (tia) | 507 | 58 | (24) | ||
| F | CCCTTCTGCATCCTTGTAAGACA | ||||
| R | TATAAGGGCGGTGATAAAAACG | ||||
| O-islands (efa/lifA) | 521 | 58 | (23) | ||
| F | GAACAAAGAACATTTTCACCAGTTC | ||||
| R | CTTTCAGGTGGGGAACCCG | ||||
| She (pic) | 606 | 57 | (23) | ||
| F | ATTCTTCTGGCTGGCATTCC | ||||
| R | CGGGATTAGAGACTATTGTTGC | ||||
| EspC (espC) | 453 | 54 | (23) | ||
| F | GCTCAACTAAATATTGATAATGTATG | ||||
| R | CCCAGCCCCAACCCTGAAAC | ||||
| Primers Used for Phylogenetic Quadruplex PCR | |||||
| chuA | |||||
| chuA.1b | F | ATGGTACCGGACGAACCAAC | 288 | 59 | (9) |
| chuA.2b | R | TGCCGCCAGTACCAAAGACA | 288 | 59 | (8) |
| yjaA | 211 | 59 | (9) | ||
| yjaA.1b | F | CAAACGTGAAGTGTCAGGAG | |||
| yjaA.2b | R | AATGCGTTCCTCAACCTGTG | |||
| TspE4.C2 | 152 | 59 | (9) | ||
| TspE4C2.1b | F | CACTATTCGTAAGGTCATCC | |||
| TspE4C2.2b | R | AGTTTATCGCTGCGGGTCGC | |||
| arpA | |||||
| AceK.f | F | AACGCTATTCGCCAGCTTGC | 400 | 59 | (9) |
| ArpA1.r | R | TCTCCCCATACCGTACGCTA | 400 | 59 | (25) |
| Primers Used for Duplex PCR | |||||
| Group E | |||||
| arpA | 301 | 57 | (26) | ||
| ArpAgpE.f | F | GATTCCATCTTGTCAAAATATGCC | |||
| ArpAgpE.r | R | GAAAAGAAAAAGAATTCCCAAGAG | |||
| trpA | 489 | 57 | (27) | ||
| trpBA.f | F | CGGCGATAAAGACATCTTCAC | |||
| trpBA.r | R | GCAACGCGGCCTGGCGGAAG | |||
| Group C | |||||
| trpA | 219 | 59 | (26) | ||
| trpAgpC.1 | F | AGTTTTATGCCCAGTGCGAG | |||
| trpAgpC.2 | R | TCTGCGCCGGTCACGCCC | |||
| trpA | 489 | 59 | (27) | ||
| trpBA.f | F | CGGCGATAAAGACATCTTCAC | |||
| trpBA.r | R | GCAACGCGGCCTGGCGGAAG | |||
Abbreviations: Bp, base pair; DEC, diarrheagenic Escherichia coli; ExPEC, extra-intestinal pathogenic E. coli; F, forward; PAIs, pathogenicity associated islands; PCR, polymerase chain reaction; R, reverse.
3.3.2. Assay of Pathogenicity Island Markers
3.3.3. Escherichia coli Phylotyping
3.4. Escherichia coli Serotyping
3.5. Statistical Analysis
4. Results
4.1. Identification of Isolates
4.2. Prevalence of Virulence and Toxin Genes
Distribution of; A, virulence; B, toxins; C, DEC PAIs; D, ExPEC PAIs; E, phylogroups; F, pathogroups among clinical and environmental Escherichia coli isolates. DEC, diarrheagenic E. coli; PAIs, pathogenicity associated islands; ExPEC, extra-intestinal pathogenic E. coli; EPEC, enteropathogenic E. coli; EHEC, enterohaemorrhagic E. coli; ETEC, enterotoxigenic E. coli; EIEC, enteroinvasive E. coli; *, significant; **, moderately significant; ***, highly significant.
| Phylogenetic Group | MVSa (No. of Isolates) | MTSb (No. of Isolates) | ||||
|---|---|---|---|---|---|---|
| All Isolates (N = 105) | Clinical Isolates (N = 72) | Environmental Isolates (N = 33) | All Isolates (N = 105) | Clinical Isolates (N = 72) | Environmental Isolates (N = 33) | |
| Total | 6.1 (105) | 6.7 (72) | 4.7 (33) | 3.2 (105) | 3.5 (72) | 2.5 (33) |
| Group A | 5.5 (18) | 6.2 (10) | 4.6 (8) | 2.3 (18) | 2.3 (10) | 2.3 (8) |
| Group B1 | 4.5 (30) | 5.9 (10) | 4.3 (20) | 2.7 (30) | 3.0 (10) | 2.5 (20) |
| Group B2 | 8.6 (18) | 8.5 (16) | 9 (2) | 2.8 (18) | 2.7 (16) | 3.5 (2) |
| Group D | 6.6 (19) | 6.8 (17) | 5 (2) | 4.4 (19) | 4.6 (17) | 2.5 (2) |
| Group C | 5.6 (12) | 5.6 (12) | - | 3.9 (12) | 3.9 (12) | - |
| Group E | 5 (3) | 5.0 (3) | - | 4.3 (3) | 4.3 (3) | - |
| Group F | 7 (3) | 7.5 (2) | 6 (1) | 3.7 (3) | 4 (2) | 3 (1) |
| Unknowns | 7.5 (2) | 7.5 (2) | - | 3.5 (2) | 3.5 (2) | - |
a MVS, mean virulence score (the sum of all VGs detected in isolates/ the number of isolates in each category per each phylogroup).
b MTS, mean toxin score (the sum of all toxin genes detected in isolates/ the number of isolates in each category per each phylogroup).
4.3. Distribution of PAIs
4.4. Phylogenetic Analysis
4.5. Escherichia coli Pathotypes
4.6. Pathogenicity Islands Combinations
Hierarchical diagram of pathogenicity island markers among 72 clinical and 33 environmental isolates based on non-possession or possession of single/multiple combinations of pathogenicity island markers. PAIs, pathogenicity associated islands. A, diarrheagenic PAI combination; B, extra-intestinal PAI combinations.
4.7. Phylogenetic Relationship with Virulence and Toxin Genes, Pathogenicity Islands and Pathotypes
5. Discussion
Comparison between clinical and environmental Escherichia coli isolates via relation between phylogeny and A, median DEC PAIs; B, median ExPEC PAIs; C, pathotypes. PAIs, pathogenicity associated islands; solid shapes, indicate clinical isolates; empty shapes, indicate environmental isolates.


